Leukemia Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

MLL AML chemo risk

A

topoisomerase II inhib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Mutation in hairy cell leukemia

A

BRAFVB600E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Indications to treat hair cell

A

Symptoms or cytopenais

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Frontline treatment for hair cell

A

cladribine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

IgVH prognosis in CLL

A

good prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ZAP7- prognosis in CLL

A

poor prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

poor prognosis cytogenetics CLL

A

del 17p

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

CLL treatment with poor performance status

A

obinutuzumab and chlorambucil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

TKI with pancreatitis AE

A

nilotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

TKI with thrombosis AE (2)

A

nilotinib and ponatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

TKI with pulmonary hypertension AE

A

dasatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

TKI with worse hepatotoxicity AE

A

bosutinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ATG treatment in MDS cellular markers

A

HLA-DR15 or STAT3 mutated T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

AML defining cytogenetic abnormalities

A

inv(16), t(8;21), t(15;17)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Favorable mutation in MDS

A

SF3B1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Germline mutations associated with MDS/AML (5)

A

RUNX1, GATA2, DDX41, CEBPA, MBD4

17
Q

Treatment of relapse HCL

A

remission >24 months: retreat with clardrabine followed by Ritux
remission <24 months: moxetumomab pasudotox + ritux